Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Summary

This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment. PS 341 is a type of drug known as a "proteasome inhibitor." By inhibiting the "proteasome" in cancer cells, PS-341 alters the way those cells divide). We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests (prostate specific antigen, also called PSA), and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer.

Timeline

Start

2005-04-30

Primary completion

2010-10-23

Completion

2012-06-11

Outcome

Outcome not reported

Stopped: “Sponsor stopped study early.”

Drugs

Indications